22,000 Shares in Krystal Biotech, Inc. $KRYS Bought by Elmind Capital LP

Elmind Capital LP purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 22,000 shares of the company’s stock, valued at approximately $8,176,740. Krystal Biotech comprises 0.0% of Elmind Capital LP’s holdings, making the stock its 15th largest position. Elmind Capital LP owned 0.07% of Krystal Biotech as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Silvant Capital Management LLC bought a new stake in Krystal Biotech during the second quarter valued at $30,000. Western Wealth Management LLC acquired a new position in shares of Krystal Biotech in the 1st quarter valued at $34,000. Greenline Wealth Management LLC bought a new position in Krystal Biotech in the fourth quarter valued at approximately $34,000. Danske Bank A S bought a new stake in shares of Krystal Biotech in the third quarter valued at about $35,000. Finally, UMB Bank n.a. raised its position in Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares in the company, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares of the company’s stock, valued at $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 51,000 shares of company stock worth $16,278,020. 13.10% of the stock is owned by insiders.

Krystal Biotech Stock Down 1.7%

Shares of NASDAQ KRYS traded down $6.06 during mid-day trading on Friday, reaching $351.40. 100,875 shares of the company were exchanged, compared to its average volume of 337,721. Krystal Biotech, Inc. has a twelve month low of $136.73 and a twelve month high of $382.54. The company’s 50-day simple moving average is $348.57 and its 200-day simple moving average is $303.83. The stock has a market capitalization of $10.40 billion, a P/E ratio of 44.04 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The business had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 7.68 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on KRYS. TD Cowen boosted their price objective on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. HC Wainwright boosted their price target on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Evercore reissued an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Finally, Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $365.40.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.